Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.56 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL27265226 | 1.00 | BHMT (0.56) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL14485913 | 1.00 | BHMT (0.56) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL27264983 | 1.00 | BHMT (0.56) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL1163782 | 1.00 | BHMT (0.56) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL2804076 | 1.00 | BHMT (0.56) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL538646 | 1.00 | BHMT (0.56) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL15323126 | 0.94 | BHMT (0.51) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL23361954 | 0.94 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL8983115 | 0.94 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL126688 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091313-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | Immunoforge Co., Ltd. (KR) | 2024-03-21 | — | — | US | disclosed |
| EP-3311828-B1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | PHASEBIO PHARMACEUTICALS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3311828-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | Phasebio Pharmaceuticals, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180008677-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | PHASEBIO PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | disclosed |
| US-9700598-B2 | Modified vasoactive intestinal peptides | PHASEBIO PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| EP-2464370-B1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | PHASEBIO PHARMACEUTICALS INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160220642-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | Immunoforge Co., Ltd. (KR) | 2016-08-04 | — | — | US | disclosed |
| US-9029505-B2 | Modified vasoactive intestinal peptides | PHASEBIO PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2464370-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | Phasebio Pharmaceuticals, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110178017-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | PHASEBIO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011020091-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | PHASEBIO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| EP-0472662-A4 | ANTIFREEZE POLYPEPTIDES | — | 1992-10-07 | — | — | EP | disclosed |
| US-5118792-A | Fusion protein containing beta-lactamase; for increasing stroage stability of food and bioligics and to protect plants from frost | DNA PLANT TECHNOLOGY CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0472662-A1 | ANTIFREEZE POLYPEPTIDES | DNA Plant Technology Corporation (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1990013571-A1 | ANTIFREEZE POLYPEPTIDES | DNA PLANT TECHNOLOGY CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180008677-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | BHMT 3631/4885BHMT2 3514/4885RNPEP 783/4885 |
| US-20110178017-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | BHMT 3631/4885BHMT2 3514/4885RNPEP 783/4885 |
| US-20240091313-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | BHMT 3631/4885BHMT2 3514/4885RNPEP 783/4885 |
| US-20160220642-A1 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES | VIP, VIPR1, VIPR2 | BHMT 3631/4885BHMT2 3514/4885RNPEP 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.